ClinicalTrials.gg
Not yet recruitingNCT07603713Updated May 22, 2026

Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis

A Phase 2 interventional study of LP-005 Injection and Placebo Injection in Periodontitis, sponsored by Longbio Pharma (Suzhou) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Longbio Pharma (Suzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Periodontitis with a site in China — 18 open to participants now, 21 under way, none of them phase 3. Periodontitis · China.

Planned enrollment
11th of 27
100 · median 90
Started
2026
with 5 others
Phase 2
2 of 38
2 open now
Primary completion
2026-11
later than 12 of 20 live
Registered
36th of 38
by date

Among the 38 studies in Periodontitis with a site in China, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2026, is one of 2 in phase 2, reaches primary completion later than 12 of the 20 other live ones, and was the 36th registered.

Periodontitis

1,235 studies on the registry are indexed under Periodontitis; 298 are open to participants now.

Browse Periodontitis studies →

Open to participants now

18 of the 38 studies in Periodontitis with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 60 (38%) stop at 75 or younger; 12 take children under 18; 77 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Periodontitis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple local injections of different doses of LP-005 injection in patients with moderate-to-severe periodontitis, and to investigate changes in biomarker levels.

03

Conditions studied

  • Periodontitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 70 years (inclusive), with no restriction on sex.
  2. Clinically diagnosed with moderate to severe (Stage II or III) periodontitis according to the 2018 International Classification of Periodontal and Peri-Implant Diseases. participants must have at least 2 non-adjacent natural teeth (excluding third molars) in the dentition with a Probing Depth (PD) of 5 to 8 mm (inclusive), and at least 1 site per tooth with a BI score > 2.
  3. Participants and their partners must agree to practice effective non-pharmacological from the time of signing the Form (ICF) until 3 months after the study completion. For female participants of , a negative pregnancy test result is required within 7 days prior to the first dose.
  4. Voluntary participation in the trial and signed approval of the ICF.

Exclusion criteria

Exclusion Criteria:

  1. At the time of screening, the target tooth and/or adjacent teeth (as determined by the investigator to affect the target tooth) exhibit periapical periodontitis, pericoronitis, or combined pulp-periodontal lesions; or the participant has orthodontic appliances (including fixed lingual retainers, etc.);
  2. At screening, the target tooth and/or adjacent teeth (as determined by the investigator to affect the target tooth) are found by the investigator to have severe caries or caries requiring immediate treatment;
  3. At screening, the participant has a periodontal or dental abscess, or a tumor of the oral soft or hard tissues;
  4. Participants who have previously undergone periodontal surgery on the target teeth and/or adjacent teeth (as determined by the investigator to affect the target teeth), or who have undergone subgingival scaling and root planning (SRP) within 6 months prior to screening;
  5. Participants with a history of Neisseria meningitidis infection;
  6. Participants with a history of splenectomy or congenital asplenia;
  7. Participants with impaired immune function (e.g., infection, neutropenia, complement deficiency, etc.);
  8. Participants with diseases that the investigator determines may interfere with the evaluation of the study disease, such as Sjögren's syndrome, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, etc.;
  9. Participants with poorly controlled blood pressure at screening, such as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
  10. Participants with (HbA1c) >7.5% or severe diabetic complications at screening;
  11. Participants with severe or poorly controlled systemic diseases at screening, as determined by the investigator, such as respiratory, gastrointestinal, cardiovascular, hematological, urological, neurological, or psychiatric disorders;
  12. Participants who have continuously taken medications deemed by the investigator to interfere with the study within 1 month prior to screening, such as nifedipine, phenytoin, or anticoagulants (e.g., warfarin);
  13. Participants who have received systemic antibiotic therapy within 3 months prior to screening;
  14. Participants who have taken nonsteroidal anti-inflammatory drugs (NSAIDs) or on a long-term basis (≥3 times per week) prior to screening;
  15. Participants with any of the following laboratory test results at the time of screening:

    • or AST > 2.5 times the (ULN) or serum total > 1.5 times ULN;
    • Serum creatinine > 1.5 times the upper ULN;
    • (INR) ≥ 1.5 times ULN, or activated partial thromboplastin time (APTT) ≥ 1.5 times ULN (excluding participants currently receiving anticoagulant therapy);
    • count (PLT) \< 100 × 10⁹/L;
  16. Participants who test positive for surface antigen (HBsAg), virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody (TP-Ab) at screening;
  17. Participants with a history of malignant tumors within 5 years prior to screening;
  18. Participants with a history of heavy smoking (≥10 cigarettes per day) within 12 months prior to screening;
  19. Participants with known allergies to any drugs or materials used during surgery;
  20. Pregnant or breastfeeding women;
  21. Participants who have participated in other clinical trials within 30 days prior to screening or who plan to participate in other clinical trials during the study period;
  22. Participants assessed by the investigator as having other conditions rendering them unsuitable for participation in the clinical study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    LP-005 Low-dose cohort

    Participants in this arm will receive LP-005 injection at a dose of 2.5 mg per injection site, with 2 injection sites per treated tooth, administered at a volume of 150 μL per site, once every 4 weeks for a total of 3 doses.

    Drug: LP-005 Injection

  • Experimental
    LP-005 Medium-dose cohort

    Participants in this arm will receive LP-005 injection at a dose of 5.0 mg per injection site, with 2 injection sites per treated tooth, administered at a volume of 150 μL per site, once every 4 weeks for a total of 3 doses.

    Drug: LP-005 Injection

  • Experimental
    LP-005 High-dose cohort

    Participants in this arm will receive LP-005 injection at a dose of 7.5 mg per injection site, with 2 injection sites per treated tooth, administered at a volume of 150 μL per site, once every 4 weeks for a total of 3 doses.

    Drug: LP-005 Injection

  • Placebo comparator
    Placebo cohort

    Participants in this arm will receive placebo injection at a dose of 0 mg per injection site, with 2 injection sites per treated tooth, administered at a volume of 150 μL per site, once every 4 weeks for a total of 3 doses.

    Drug: Placebo Injection

Interventions

  • LP-005 is a bifunctional antibody fusion protein consisting of an anti-human C5 monoclonal antibody and a human complement regulatory protein, formulated as a sterile injectable solution. Each vial contains 300 mg of LP-005 in 6 mL (50 mg/mL). The LP-005 is administered via interdental papilla injection.

  • DrugPlacebo Injection

    Placebo is a sterile injectable solution matched to LP-005 for appearance, formulation, and administration, with 0 mg of active ingredient per 6 mL vial.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Gingival Index (GI)

    GI is measured using the Löe-Silness scale (range: 0-3), where higher scores indicate more severe gingival inflammation (worse outcome). Changes from baseline in gingival index (GI) scores are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.

    Time frame: Day 43, Day 85, Day 127, and Day 169

  2. Change from Baseline in Bleeding Index (BI)

    BI is measured using the Caton-Paton scale (range: 0-4), where higher scores indicate more severe gingival bleeding (worse outcome). Changes from baseline in BI scores are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.

    Time frame: Day 43, Day 85, Day 127, and Day 169

  3. Change from Baseline in Probing Pocket Depth (PD)

    Changes from baseline in probing pocket depth (PD) are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.

    Time frame: Day 43, Day 85, Day 127, and Day 169

  4. Change from Baseline in Clinical Attachment Loss (AL)

    Clinical AL is evaluated by standardized periodontal probing: after measuring probing depth, the probe tip is withdrawn along the root surface to identify the cemento-enamel junction (CEJ). The distance from the CEJ to the gingival margin (GM) is recorded. AL is calculated by subtracting this distance from the probing depth. A result of zero or an undetectable CEJ indicates no attachment loss. In cases of gingival recession where the gingival margin is apical to the CEJ, AL is determined by summing the two measurements. Six sites per tooth are examined, and AL values are recorded at all measured sites, with units expressed in millimeters (mm); larger values represent more severe periodontal attachment destruction. Changes from baseline in AL are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.

    Time frame: Day 43, Day 85, and Day 127, Day 169

  5. Change from Baseline in Plaque Index (PI)

    PI is measured using the Silness-Löe scale (range: 0-3), higher scores indicate thicker dental plaque accumulation and more severe periodontal plaque condition. Changes from baseline in plaque index (PI) scores are measured at Day 43, Day 85, Day 127, and Day 169 after the first administration of LP-005 injection.

    Time frame: Day 43, Day 85, Day 127, and Day 169

  6. Change from Baseline in Alveolar Bone Defect Height

    Changes from baseline in alveolar bone defect height are measured at Day 85 and Day 169 after the first administration of LP-005 injection, assessed via cone-beam computed tomography (CBCT).

    Time frame: Day 85, and Day 169

  7. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Incidence and severity of TEAEs from first dose to end of study are recorded.

    Time frame: Up to approximately 24 weeks

  8. Detect Pharmacokinetic (PK) Characteristics of LP-005

    Assess detectable serum concentration of LP-005 after local administration; if sufficient systemic exposure is detected, evaluate the systemic plasma PK characteristics of LP-005.

    Time frame: Up to approximately 24 weeks

  9. Gingival Crevicular Fluid (GCF) Concentration of LP-005

    GCF samples to evaluate changes in LP-005 concentration in participants' GCF after local administration.

    Time frame: Up to approximately 24 weeks

  10. Detect Pharmacodynamics (PD) Characteristics of LP-005

    Collect systemic venous blood samples to evaluate changes in participants' serum complement hemolytic activity (CH50), free C5 level, and C3b deposition after local administration of LP-005.

    Time frame: Up to approximately 24 weeks

  11. Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Assessment

    Collect systemic venous blood samples to evaluate the positivity rate of ADA in participants, the titer of ADA-positive samples, and further detect NAb in ADA-positive samples.

    Time frame: Up to approximately 24 weeks

Secondary outcomes

  1. Change from Baseline in Gingival Crevicular Fluid (GCF) Biomarker Levels

    GCF samples will be collected in participants' GCF after local administration of LP-005 to assess changes from baseline in a predefined panel of inflammatory and tissue-degrading biomarkers, including C3b, C5a, IL-1β, IL-6, TNF-α, MMP-8, and MMP-9. All biomarkers are quantified in standardized protein concentration units within GCF, and individual biomarker changes will be reported separately without aggregation.

    Time frame: Up to approximately 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

Of 18 phase 2 interventional studies under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 22, 2026
StartEst.
May 1, 2026
Primary completionEst.
Nov 12, 2026
CompletionEst.
Mar 23, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07603713
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Nov 12, 2026 (estimated)
Completion
Mar 23, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Jie Yang
Contact
yangj@longbiopharma.com
+86 021-58372390
Hong Hua
principal investigator · Peking University School and Hospital of Stomatology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-005

Start the discussion